Immunotec is an active nutritional-supplement and wellness direct-selling company operating at Immunotec.com. The company was founded in 1996 and built its business around Immunocal, a glutathione-focused dietary supplement tied to research by Dr. Gustavo Bounous, Dr. Patricia Kongshavn, and related McGill University research history. Immunotec's current product line includes Immunocal, Immunocal Platinum, protein and weight-management products such as Shake It Up, Multi+Resveratrol, XeTRM, Xtra Sharp, and other wellness products positioned around immune support, energy, digestion, relaxation, skin health, and general nutrition.
Immunotec operates as a direct-selling / MLM company through independent Consultants. The Direct Selling Association lists Immunotec Research Inc. as a member company in health, fitness, wellness, nutritional supplements, and personal care, with a person-to-person sales strategy. Immunotec's compensation materials state that Consultants may earn from product sales, customer activity, and team volume, and that the company pays no compensation simply for enrolling new Consultants.
The company went private in 2017 through an acquisition by Immuno Holding S.A. de C.V., with Immuno Holding agreeing to acquire Immunotec's outstanding shares for C$0.485 per share. At the time of the transaction announcement, Immunotec described itself as a Canadian-based company selling research-driven nutritional, skin-care, and wellness products through direct-to-consumer channels in Canada, the United States, Mexico, the Dominican Republic, the United Kingdom, and Ireland, with a network of more than 100,000 independent Consultants.
Immunotec's regulatory and self-regulatory history includes a 2022 DSSRC inquiry involving health-related product claims and earnings claims. DSSRC reviewed claims suggesting Immunotec products could address serious health conditions including cancer, pneumonia, infertility, autism, and viruses, as well as earnings claims that could imply significant or long-term income. Immunotec removed or modified several challenged claims, and DSSRC recommended discontinuing unsupported earnings language that could suggest typical Consultants could expect substantial income. Immunotec's 2025 U.S. income disclosure reported that 73.3% of active U.S. Consultants were paid at the Entrepreneur Consultant rank with average monthly commission earnings of $0, while higher ranks represented small percentages of active Consultants.